Abstract
In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.
| Original language | English |
|---|---|
| Pages (from-to) | 770-774 |
| Number of pages | 5 |
| Journal | Haematologica |
| Volume | 93 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 2008 |
Fingerprint
Keywords
- Chronic myeloid leukemia
- Imatinib
- Interferon-alpha
- Long-term results
ASJC Scopus subject areas
- Hematology
Cite this
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α : 5-year outcome. / Palandri, Francesca; Iacobucci, Ilaria; Castagnetti, Fausto; Testoni, Nicoletta; Poerio, Angela; Amabile, Marilina; Breccia, Massimo; Intermesoli, Tamara; Iuliano, Francesco; Rege-Cambrin, Giovanna; Tiribelli, Mario; Miglino, Maurizio; Pane, Fabrizio; Saglio, Giuseppe; Martinelli, Giovanni; Rosti, Gianantonio; Baccarani, Michele.
In: Haematologica, Vol. 93, No. 5, 05.2008, p. 770-774.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α
T2 - 5-year outcome
AU - Palandri, Francesca
AU - Iacobucci, Ilaria
AU - Castagnetti, Fausto
AU - Testoni, Nicoletta
AU - Poerio, Angela
AU - Amabile, Marilina
AU - Breccia, Massimo
AU - Intermesoli, Tamara
AU - Iuliano, Francesco
AU - Rege-Cambrin, Giovanna
AU - Tiribelli, Mario
AU - Miglino, Maurizio
AU - Pane, Fabrizio
AU - Saglio, Giuseppe
AU - Martinelli, Giovanni
AU - Rosti, Gianantonio
AU - Baccarani, Michele
PY - 2008/5
Y1 - 2008/5
N2 - In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.
AB - In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-α in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-α. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-a remains uncertain, due to low patient compliance.
KW - Chronic myeloid leukemia
KW - Imatinib
KW - Interferon-alpha
KW - Long-term results
UR - http://www.scopus.com/inward/record.url?scp=43449118108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449118108&partnerID=8YFLogxK
U2 - 10.3324/haematol.12265
DO - 10.3324/haematol.12265
M3 - Article
VL - 93
SP - 770
EP - 774
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 5
ER -